Zura Bio
ZURA
Market cap $312M

4.89 USD

+0.36

7.95%

At close Oct 17, 4:00 PM EDT

After hours

5.02

+0.13

2.66%

1 day

7.95%

5 days

27.01%

1 month

26.03%

3 months

39.71%

6 months

56.23%

Year to date

12.41%

1 year

-17.12%

5 years

-32.46%

About: Zura Bio Ltd is a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders.

Employees: 15

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,740 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

205% more capital invested

Capital invested by funds: $37.6M [Q1] → $115M (+$77.3M) [Q2]

200% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 6

110% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 10

27% more funds holding

Funds holding: 45 [Q1] → 57 (+12) [Q2]

17.47% more ownership

Funds ownership: 34.22% [Q1] → 51.69% (+17.47%) [Q2]

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$5

2%

upside

Avg. target

$15.50

217%

upside

High target

$26

432%

upside

2 analyst ratings

1 positive

50%

1 neutral

50%

0 negative

0%

Piper Sandler Yasmeen Rahimi 70% 1-year accuracy 16 / 23 met price target	432%upside $26	Overweight Maintained	19 Sept 2024
HC Wainwright & Co. Mitchell Kapoor 51% 1-year accuracy 64 / 125 met price target	2%upside $5	Neutral Initiated	5 Sept 2024

See Analyst Rankings

Financial journalist opinion

Zura Bio to Present at Three Upcoming Investor Conferences in September

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of its senior leadership team will present at three upcoming investor conferences in September. Conference Details: Event: H.C. Wainwright 26th Annual Global Investment Conference Details: Presenting on Wednesday, September 11, 2024, at 11:30 a.m. ET and hos.

Zura Bio to Present at Three Upcoming Investor Conferences in September

CPS HR Consulting Partners with GovInvest to Revolutionize Compensation Consulting with Advanced Technology

SACRAMENTO, Calif.--(BUSINESS WIRE)--CPS HR Consulting, a leader in public sector HR consulting, is thrilled to announce a strategic partnership with GovInvest, the pioneer of compensation analytics technology for government agencies. This collaboration aims to combine CPS HR's renowned compensation consulting expertise with GovInvest's innovative software platform, offering unparalleled data confidence and decision-making capabilities. Highlights of the Partnership Best-in-Class Consulting + T.

CPS HR Consulting Partners with GovInvest to Revolutionize Compensation Consulting with Advanced Technology

Zura Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported its second quarter 2024 financial results, and recent business highlights. "We have made meaningful progress on our key development programs this quarter. Highlights include selecting our CRO for the Phase 2 clinical program in SSc and advancing study start-up activities.

Zura Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Zura Bio Completes Exchange Offer and Consent Solicitation and Notice to Exercise Right to Exchange Remaining Outstanding Warrants

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that it has completed its previously announced exchange offer (the “Exchange Offer”) and consent solicitation (the “Consent Solicitation”) relating to its outstanding (i) public warrants that were issued in connection with its initial public offering to purchase Clas.

Zura Bio Completes Exchange Offer and Consent Solicitation and Notice to Exercise Right to Exchange Remaining Outstanding Warrants

Zura Bio Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to its Warrants

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced the expiration and results of its previously announced exchange offer (the “Exchange Offer”) and consent solicitation (the “Consent Solicitation”) relating to its outstanding (i) public warrants that were issued in connection with its initial public offering to purch.

Zura Bio Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to its Warrants

3 Undervalued Biotech Stocks With Breakout Potential

Undervalued biotech stocks will always be relevant for the savvy investor. The biotech world is evolving rapidly, with pharmaceutical giants tirelessly building on their pipelines and technologies.

3 Undervalued Biotech Stocks With Breakout Potential

Zura Bio Commences Warrant Exchange Offer and Consent Solicitation

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (NASDAQ: ZURA) (“Zura Bio” or the “Company”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that it has commenced an exchange offer (the “Offer”) and consent solicitation (the “Consent Solicitation”) relating to its outstanding (i) public warrants that were issued in connection with its initial public offering to purchase Class A ordinary shares of the Comp.

Zura Bio Commences Warrant Exchange Offer and Consent Solicitation

The 3 Most Undervalued Biotech Stocks to Buy in July 2024

There's always a strong case for undervalued biotech stocks. For one, the industry is only expected to grow.

The 3 Most Undervalued Biotech Stocks to Buy in July 2024

Zura Bio Presents Data for the Tibulizumab (ZB-106) Program at EULAR 2024

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today shared supportive data from a Phase 1 study evaluating its lead candidate, tibulizumab (ZB-106), for the treatment of Sjogren's syndrome. These data, along with preclinical data supporting further development of tibulizumab in rheumatoid arthritis (RA), were presented at the Annual European Co.

Zura Bio Presents Data for the Tibulizumab (ZB-106) Program at EULAR 2024

Zura Bio Forms Scientific Advisory Board with Prominent Specialists in Rheumatology, Dermatology, and Immunology

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Forms Scientific Advisory Board with Prominent Specialists.

Zura Bio Forms Scientific Advisory Board with Prominent Specialists in Rheumatology, Dermatology, and Immunology

See News Rankings

Charts implemented using Lightweight Charts™